The 76% profit surge that's 80% margin, not volume

The headline profit jump is real. But here's the gap: revenue grew 10.4%, PAT grew 75.9%. That 7.3x leverage didn't come from volume — it came from a ferocious portfolio mix shift and margin expansion. Total IMFL volume was up just 3% YoY, at 10 million cases. All the growth came from premiumization: Prestige & Above surged 36%, while the regular segment declined. This is premiumization's promise proved, but at a tactical cost that management hasn't fully admitted yet.

Start with gross margin: it expanded 610 bps YoY to 49.1%, driven by (i) benign raw material costs (the last two years' ENA and spirit price softness held), and (ii) price increases that yielded +75 bps of expansion. The company absorbed a ₹30 Cr packing material headwind from West Asia volatility and still expanded. EBITDA margin hit 20.7%, a 536 bps jump — exceeding the prior 125 bps target. Magic Moments delivered 43% volume and 51% value growth, now 3.25 million cases with a 75% flavored mix (up from 65%). But here's the rub: total volume growth was only 3% because the regular category (non-P&A spirits, home category) contracted year-on-year. Andhra Pradesh's route-to-market change (a high prior-year base), Maharashtra's Malt Made Liquor introduction (industry down 35% FY26, −20% Q1), and Karnataka pricing reforms all hit the regular segment hard. Without these policy headwinds, would regular have grown? Probably 5–10%. The net effect: a portfolio mix that's 80% of earnings growth, not volume.

Management raised P&A volume guidance from 20% to 25% for FY27 — but Q1 already delivered 36%, so the new range is still conservative. Luxury portfolio (₹475 Cr base FY26) is reconfirmed on track for 25% value growth (₹594+ Cr FY27 target); Rampur, Virasat, Royal Ranthambore all tracking. EBITDA margin guidance was set at ~20% for FY27 — management achieved 20.7% in Q1, so they guided the midpoint. Debt-free by Q2 FY27 is confirmed; net debt was ₹138 Cr lower than March 2026. The regular segment narrative shifted from 'growth' to 'profitable states only' — management de-emphasized this once-core category. Morpheus prestige whisky got a cautious tone: 'initial traction, but it's a journey' — no volume targets, no scaling clarity. Capex was anchored at ₹150–170 Cr annually, maintenance-only, no major expansion. The tequila launch and vodka flavor innovation (ethnic India focus) are the growth levers alongside P&A core, not Morpheus.

The market's verdict was mixed. On day 1 post-result, the stock rose +1.96% with 30.8% delivery participation. By day 3, momentum had faded to +1.19% — but by day 5, it recovered to +3.74% over the announcement price of ₹4,289.7, settling at ₹4,450. The move *held*, suggesting the street validated the beat. But here's the rub: FII are trimming (down 2.19pp to 17.63%) while domestic institutions (DII) are accumulating (up 3.32pp to 27.35%). This is a classic tell — overseas money taking profit on a high, local money buying on the story. The stock is trading 78% off its 52-week low, near its all-time high, with RSI at 75.3 (overbought territory). Volume trend is increasing, but the technical setup suggests limited room to run without a fresh fundamental catalyst. The market loves the premiumization thesis but is pricing in most of the near-term upside already.